



NEWSLETTER

AUG, 2025 VOL. 66

A company that thinks of people, Intolnworld Co., Ltd.

"From people to people, connecting the value of clinical trials."

We strive to become a bridge of trust that safely delivers the value of medicine to people, and to be a true partner that always grows together with our clients through people-centered thinking.

Intolnworld Co., Ltd., established in 2015, is a Clinical Research Organization (CRO) that professionally conducts clinical trials in all fields, including pharmaceuticals, biotechnology, medical devices, IIT, and OS.

KONECT-MOHW-MFDS International Conference 2025 Booth Participation

Date : 22-24 September

Vanue : 2/F, 3/F, Lotte Hotel Seoul, 30 Eulji-ro, Jung-gu, Seoul
Booth : Booth 44, 2/F

Intolnworld will be participating in the KONECT-MOHW-MFDS International Conference 2025 from September 22 to 24!

We look forward to your great interest and visit, and we hope to see you at the event!

2025 KIC

D-30

2025 KONECT-MOHW-MFDS INTERNATIONAL CONFERENCE

Transforming Clinical Trials Through Technology, Diversity and Collaboration

2025.9.22. - 9.24.
LOTTE Hotel Seoul

1 Sep 22

Plenary Lecture 1 — 09:30 AM

Yul Hong Kim
Head of R&D, Yuhon Corporation

Plenary Session 1 — 10:30 AM

AI and Big Data in Drug Development
Breaking Barriers, Building Futures

1 Sep 23

Plenary Lecture 2 — 09:00 AM

Inhee Moon-Jung
Professor, Seoul National University

Plenary Session 1 — 10:30 AM

Korea's Clinical Trials at a Crossroads:
Revisiting Strengths, Rethinking Strategies

Plenary Lecture 3 — 09:30 AM

Shahin Rescu
CEO, Mesocast

REGISTER NOW

GLOBAL PHARMACEUTICAL COMPANIES TURN TO KOREA FOLLOWING CHINA... CONTRACT SIZE INCREASES BY 113%

This year, the scale of global technology transfer deals by domestic pharmaceutical companies has nearly doubled compared to last year. With successive contracts signed with major overseas pharmaceutical companies, Korea has emerged as a key hub for discovering innovative new drug candidates. Experts assess that, fueled by government support and expanded international investment, opportunities are growing and Korea's strategic position in the global market is strengthening.

**'TALENT DEVELOPMENT' URGENTLY NEEDED IN THE
PHARMACEUTICAL AND BIOTECH INDUSTRY...
"PUBLIC AND PRIVATE SECTORS MUST COLLABORATE"**

The domestic pharmaceutical and biotechnology industry is expanding in scale with the influx of young talent, but a shortage of research and development personnel and talent concentration are being pointed out as problems. The limitations of a sales-centered structure and the urgent need for education and government support to address workforce shortages are emphasized, along with the necessity of systematic talent cultivation to strengthen competitiveness in new drug development.

☎ 02-2038-8082

🌐 www.intoinworld.com

✉ bd@intoinworld.kr



NEWSLETTER

AUG, 2025 VOL. 66



GOVERNMENT PLANS TO BUILD A HEALTHCARE DATA INTEGRATION AND UTILIZATION PORTAL BY THE SECOND HALF OF 2027

The government will promote digital healthcare innovation through an integrated healthcare data portal in the second half of 2027. With the Digital Healthcare Act and vouchers, it plans to support data utilization and personal information protection, open bio big data from one million people starting in 2026, and accelerate medical AI development through AI healthcare collaboration.

"THE HIGH GROWTH OF IMMUNOLOGY IS OVER"... INNOVATION FOCUSED ON SMALLER-SCALE DISEASES NEEDED

The global immunology market has entered a mature stage, with slowing growth and intensifying competition. Autoimmune diseases are expected to grow by 4%, while inflammatory diseases are projected to grow by 14%. Price competition is intensifying due to biosimilars, raising concerns about declining profitability. Pharmaceutical companies are shifting toward niche diseases, and innovative mechanisms and patient-centered value are expected to determine the market's success or failure.



"COLLABORATION BETWEEN RELEVANT MINISTRIES AND INSTITUTIONS IS CRUCIAL FOR INSTITUTIONALIZING ALTERNATIVE ANIMAL TESTING METHODS"

With the abolition of animal testing in the U.S. and Europe, there are growing calls for Korea to also legislate an animal testing alternatives act. As competition intensifies in organoid (mini artificial organ) and AI toxicity prediction technologies, proposals have been made for Korea to quickly legislate and standardize animal testing alternatives, establish infrastructure, and create an integrated government response and support system encompassing inter-ministerial cooperation.

